skip to main content
Show Results with:

Treatment outcomes of hepatectomy for liver metastases of gastric cancer diagnosed using contrast-enhanced magnetic resonance imaging

Gastric Cancer, 2017, Vol.20(2), pp.387-393 [Peer Reviewed Journal]

Full text available

  • Title:
    Treatment outcomes of hepatectomy for liver metastases of gastric cancer diagnosed using contrast-enhanced magnetic resonance imaging
  • Author: Tatsubayashi, Taichi ; Tanizawa, Yutaka ; Miki, Yuichiro ; Tokunaga, Masanori ; Bando, Etsuro ; Kawamura, Taiichi ; Sugiura, Teiichi ; Kinugasa, Yusuke ; Uesaka, Katsuhiko ; Terashima, Masanori
  • Found In: Gastric Cancer, 2017, Vol.20(2), pp.387-393 [Peer Reviewed Journal]
  • Subjects: Gastric cancer ; Liver metastasis ; Hepatectomy
  • Language: English
  • Description: To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s10120-016-0611-7 Byline: Taichi Tatsubayashi (1), Yutaka Tanizawa (1), Yuichiro Miki (2), Masanori Tokunaga (1), Etsuro Bando (1), Taiichi Kawamura (1), Teiichi Sugiura (3), Yusuke Kinugasa (3), Katsuhiko Uesaka (3), Masanori Terashima (1) Keywords: Gastric cancer; Liver metastasis; Hepatectomy Abstract: Background Chemotherapy is the standard treatment for liver metastases of gastric cancer (LMGC). Hepatectomy for LMGC reportedly has a 5-year survival rate of 13--37 % however, its significance has not been established. At our hospital, hepatectomy is performed for patients with three or fewer metastases diagnosed using contrast-enhanced magnetic resonance imaging (MRI). To identify the ideal patient subpopulation for resection, we retrospectively analyzed treatment outcomes in patients with LMGC who underwent hepatectomy. Methods Clinicopathological factors affecting survival were explored using univariate and multivariate analyses in 28 patients who underwent hepatectomy for LMGC diagnosed using contrast-enhanced MRI between December 2004 and October 2014. Results The study included 23 men and 5 women with a median age of 72 years. Metastases were synchronous in 15 patients and metachronous in 13 patients. The median overall survival time was 49 months, with a 5-year survival rate of 32 %. Univariate analysis revealed that overall survival time was shorter in the presence of the following factors: age a[yen]70 years (p = 0.030), synchronous liver metastases (p = 0.017), and presence of postoperative complications (p = 0.042). In patients with metachronous liver metastases, the post-resection 5-year survival rate was 59 %. Conclusions The 5-year survival rate was 32 % in patients who underwent hepatectomy for LMGC according to our criteria, suggesting that hepatectomy is an important treatment if indications are on the basis of contrast-enhanced MRI. Therefore, active resection should be considered, particularly for patients with metachronous liver metastases. Author Affiliation: (1) Division of Gastric Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan (2) Department of Surgical Oncology Graduate School of Medicine, Osaka City University, Osaka, Japan (3) Division of Gastrointestinal Surgery, Shizuoka Cancer Center, Shizuoka, Japan Article History: Registration Date: 25/04/2016 Received Date: 19/11/2015 Accepted Date: 23/04/2016 Online Date: 07/05/2016
  • Identifier: ISSN: 1436-3291 ; E-ISSN: 1436-3305 ; DOI: 10.1007/s10120-016-0611-7

Searching Remote Databases, Please Wait